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Abdominal fat mass is associated with adaptive immune activation: The CODAM
study
Abstract
Abdominal fat-related activation of the innate immune system and insulin resistance (IR) are implicated in
the pathogenesis of cardiovascular diseases. Recent data support an important role of the adaptive
immune system as well. In this study, we investigate the association between waist circumference and
markers of systemic adaptive immune activation, and the potential mediating role of innate immune
activation and/or IR herein. The study population consisted of 477 (304 men) individuals (mean age:
59.4±7.0 years) in whom waist circumference, HOMA2-IR (IR derived from homeostasis model
assessment), and markers of innate (C-reactive protein (CRP), interleukin (IL)-6, serum amyloid A (SAA))
and adaptive (neopterin, soluble CD25 (sCD25)) immune activation were measured. These markers were
compiled into an adaptive and innate immune activation score by averaging the respective z-scores. After
adjustments for age, sex, glucose metabolism, smoking status, prior cardiovascular disease, and other
risk factors, waist circumference was associated with the adaptive (standardized regression coefficient Β
= 0.12 (95% confidence intervals: 0.04-0.20)) and the innate immune activation scores (Β = 0.24
(0.17-0.31)), and with HOMA2-IR (Β = 0.49 (0.42-0.56)). The innate immune activation score and
HOMA2-IR were also positively associated with the adaptive immune activation score (Β = 0.31
(0.21-0.40) and Β = 0.11 (0.02-0.21), respectively). The association between waist circumference and the
adaptive immune activation score was completely abolished when further adjusted for innate immune
activation and HOMA2-IR (to Β = 0.01 (0.10-0.08)), and the specific mediation effects attributable to each
of these variables were 58% and 42%, respectively. We conclude that abdominal obesity is associated
with systemic adaptive immune activation and that innate immune activation and IR constitute
independent and equally important pathways explaining this association. 2011 The Obesity Society.
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Abdominal Fat Mass Is Associated
With Adaptive Immune Activation:
The CODAM Study
Marielle M. Thewissen1,2, Jan G. Damoiseaux1, Adriaan M. Duijvestijn1,2,
Marleen M. van Greevenbroek2,3, Carla J. van der Kallen2,3, Edith J. Feskens4, Ellen E. Blaak5,6,
Casper G. Schalkwijk2,3, Coen D. Stehouwer2,3, Jan W. Cohen Tervaert1,2 and Isabel Ferreira2,3,7
Abdominal fat–related activation of the innate immune system and insulin resistance (IR) are implicated in the
pathogenesis of cardiovascular diseases. Recent data support an important role of the adaptive immune system as
well. In this study, we investigate the association between waist circumference and markers of systemic adaptive
immune activation, and the potential mediating role of innate immune activation and/or IR herein. The study population
consisted of 477 (304 men) individuals (mean age: 59.4 ± 7.0 years) in whom waist circumference, HOMA2-IR
(IR derived from homeostasis model assessment), and markers of innate (C-reactive protein (CRP), interleukin (IL)-6,
serum amyloid A (SAA)) and adaptive (neopterin, soluble CD25 (sCD25)) immune activation were measured. These
markers were compiled into an adaptive and innate immune activation score by averaging the respective z-scores. After
adjustments for age, sex, glucose metabolism, smoking status, prior cardiovascular disease, and other risk factors,
waist circumference was associated with the adaptive (standardized regression coefficient β = 0.12 (95% confidence
intervals: 0.04–0.20)) and the innate immune activation scores (β = 0.24 (0.17–0.31)), and with HOMA2-IR (β = 0.49
(0.42–0.56)). The innate immune activation score and HOMA2-IR were also positively associated with the adaptive
immune activation score (β = 0.31 (0.21–0.40) and β = 0.11 (0.02–0.21), respectively). The association between waist
circumference and the adaptive immune activation score was completely abolished when further adjusted for innate
immune activation and HOMA2-IR (to β = −0.01 (−0.10–0.08)), and the specific mediation “effects” attributable to each
of these variables were 58% and 42%, respectively. We conclude that abdominal obesity is associated with systemic
adaptive immune activation and that innate immune activation and IR constitute independent and equally important
pathways explaining this association.
Obesity (2011) 19, 1690–1698. doi:10.1038/oby.2010.337

Introduction

Obesity, in particular abdominal obesity, increases the risk of
several chronic diseases such as hypertension, diabetes, and
cardiovascular diseases (1). Although the underlying pathophysiological mechanisms explaining these associations have
not been completely unraveled, chronic low-grade inflammation and insulin resistance (IR), which are intertwined, are
thought to play a key role in these (abdominal) obesity-related
complications (2–5).
Inflammation associated with excessive abdominal fat mass
starts locally in the adipose tissue (6). With increasing obesity,

proinflammatory macrophages accumulate in adipose tissue
(7). Adipose tissue macrophages are responsible for almost all
adipose tissue tumor necrosis factor-α and contribute significantly to adipose tissue–derived interleukin-6 (IL-6) (7), molecules involved in systemic IR (8,9). Although research so far
has focused mainly on innate immune mechanisms and markers of obesity-related inflammation, recent observations have
drawn some attention to the role of adaptive immune mechanisms in obesity and related sequelae. Indeed, accumulation of
adaptive immune cells, such as T cells, has been demonstrated
in adipose tissue in obesity (10,11). Moreover, several recent
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studies suggest that T lymphocytes are crucially involved in
the initiation and maintenance of adipose tissue inflammation
and systemic IR (11–14). It should be noted that most of these
data were obtained in mouse models of obesity and focused
on the local inflammatory process in adipose tissue. However,
the extent to which these mechanisms translate to humans
and are operable at the systemic level is largely unknown. To
that aim, investigating associations of (central) obesity with
markers discerning between the innate and adaptive immune
activation, as well as the role of IR herein, may thus enable a
better understanding of these mechanisms. Macrophages are
a major source of circulating IL-6 (7), which induces hepatic
production of acute phase reactants such as C-reactive protein (CRP) and serum amyloid A (SAA). The levels of these
molecules are commonly used as markers of activation of
the innate immune system (15). On the other hand, levels of
soluble CD25 (sCD25) and neopterin can be considered as
markers of adaptive immune activation. Production of the
soluble IL-2 receptor (sCD25) is associated with T-cell activation in vitro (16,17). In addition, increased serum sCD25 levels
have been associated with lymphocyte activation in infection,
autoimmune diseases and hematologic malignancies (18–20).
Neopterin, a product of interferon-γ–activated monocytes/
macrophages is a sensitive indicator of cell-mediated immune
activation. In humans, increased concentrations of neopterin
in serum and urine have been found during allograft rejection
episodes and in various malignant disorders, autoimmune diseases, and viral infections (21).
In view of these considerations, we have examined, in a large
cohort of individuals at increased risk of diabetes and cardiovascular disease: (i) whether waist circumference, a surrogate
marker of abdominal fat mass (22), is associated with adaptive
immune activation, as characterized by elevations in neopterin
and sCD25, and (ii) the extent to which any such associations
are explained, i.e., are potentially mediated, by innate immune
activation and/or IR.
Methods and Procedures
Subjects and study design
We used data from the Cohort of Diabetes and Atherosclerosis
Maastricht Study, an ongoing prospective cohort study in the
Netherlands that was originally designed to study the effects of obesity,
glucose tolerance, lipid metabolism, lifestyle and genetics on cardiovascular complications, and that has been described in detail elsewhere
(23,24). Briefly, between 1999 and 2001 subjects were selected from a
large population-based cohort and included if they had white ethnicity
and were older than 40 years and one or more of the following criteria:
BMI >25 kg/m2, positive family history for type 2 diabetes mellitus, history of gestational diabetes, postprandial blood glucose >6.0 mmol/l,
glucosuria, or use of antihypertensive medication. In total, 574 subjects
were included and were extensively characterized with regard to their
metabolic, cardiovascular, and lifestyle risk profiles during two visits to
the University’s research unit. For the present study, we excluded subjects with missing data on markers of adaptive and/or innate immune
activation, IR and/or important covariates (n = 87) and those on insulin
treatment (n = 10), and thus the total study population consisted of
477 individuals. Subjects excluded (n = 97) did not differ from those
included with regard to levels of waist circumference and other cardiovascular risk factors (data not shown).
obesity | VOLUME 19 NUMBER 8 | August 2011

All subjects gave written informed consent and the study was approved
by the medical ethical committee of the Maastricht University Medical
Centre.
Anthropometrics
Height (in cm) was measured with subjects standing upright against a
stadiometer. Body weight was measured to the nearest 100 g on electronic weight scales. BMI was calculated by dividing weight by height
squared and expressed in kg/m2. Waist circumference was measured
with a flexible tape at the level midway between the lowest rib and the
iliac crest.
IR and markers of innate immune activation
Subjects were asked to stop their lipid-lowering medication 14 days
prior to the blood withdrawals and to refrain from eating and drinking
after 10:00 pm in the evening before. After an overnight fast (duration
of at least 10 h), subjects underwent a standard 75-g oral glucose tolerance test with venous blood sampling. Fasting plasma glucose and postload glucose levels were measured with a glucose hexokinase-6 method
(ABX Diagnostics, Montpellier, France). Subjects’ glucose metabolism
status (i.e., normal, impaired or type 2 diabetes) was defined according
to the World Health Organization’s criteria of 1999 (25). IR was derived
from the homeostasis model assessment (HOMA2-IR) with the use of
software downloaded at http://www.dtu.ox.ac.uk.
High sensitivity CRP was measured in serum with a high sensitivity kit
(Latex; Roche Diagnostics Netherlands, Almere, the Netherlands). IL-6
was measured in EDTA plasma with a high sensitivity human Quantikine
enzyme-linked immunosorbent assay kit (R&D systems, Minneapolis,
MN). SAA was measured in EDTA plasma using a human invitrogen
enzyme-linked immunosorbent assay kit (Biosource International,
Camarillo, CA).
Markers of adaptive immune activation
Neopterin was measured using a commercially available competitive
enzyme-linked immunosorbent assay (IBL, Hamburg, Germany),
according to the manufacturer’s instructions. sCD25 was measured by
a sandwich enzyme-linked immunosorbent assay using a commercially
available antibody pair obtained from Diaclone (Diaclone Research,
Besancon, France). Both markers were measured in serum samples.
Both intra-assays coefficients of variation were <10%.
Other risk factors
Glycated hemoglobin (HbA1c) was determined by ion-exchange highperformance liquid chromatography (HPLC; Bio-Rad, Veenendaal,
the Netherlands). Total and high-density lipoprotein cholesterol and
triglycerides were measured in EDTA plasma by enzymatic methods
(Roche, Mannheim, Germany), and low-density lipoprotein cholesterol
was calculated according to the Friedwald formula.
Systolic and diastolic blood pressure were measured twice on each visit,
and the mean values were used in the analyses; readings were taken on
the right arm, with subjects in the supine position after they had rested
for 5 min, with the use of an oscillometric device (Maxi stable 3; Speidel &
Keller, currently: Welch Allyn, Skaneateles Falls, NY). Pulse pressure was
calculated as systolic blood pressure−diastolic blood pressure, mean arterial pressure as diastolic blood pressure+1/3 pulse pressure and hypertension was defined as systolic blood pressure/diastolic blood pressure
≥140/90 and/or the use of antihypertensive medication (26).
Smoking behavior was assessed by means of questionnaires and subjects were categorized into never, ex- and current smokers. Use of blood
pressure-, glucose- or lipid-lowering medication was also assessed by
questionnaire. Prior cardiovascular disease was defined as the occurrence
of myocardial infarction, bypass of the coronary arteries, percutaneous
coronary intervention, stroke, or nontraumatic limb amputation (ascertained by questionnaire), and/or the presence of signs of myocardial infarction (i.e., Minnesota codes 1–1 or 1–2) or ischemia (i.e., Minnesota
codes 1–3, 4–1, 4–2, 4–3, 5–1, 5–2, 5–3 or 7–1) on a 12-lead electrocardiography, and/or an ankle-brachial index <0.9 in either leg.
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Figure 1 Illustration of a simple mediation model (a,b) and a
multiple mediation model with two mediators (M1 and M2) (a,c), in the
context of the present study. (a) Total “effect” of waist circumference
(X: independent variable) on adaptive immune activation score (Y:
dependent variable)—path c. (b) Waist circumference is hypothesized
to exert indirect “effects” on adaptive immune activation score through
a given mediator (M: innate immune activation score or insulin
resistance—log10HOMA2-IR); this figure thus represents both the
direct effect of X on Y (path c′) and the indirect effect of X on Y through
M is defined by the product of the 2 paths linking X to Y through
that mediator (path ab). (c) Waist circumference is hypothesized to
exert indirect “effects” on adaptive immune activation score through
both innate immune activation score (M1) and insulin resistance—
log10HOMA2-IR (M2); this figure thus represents both the direct
effect of X on Y (path c′) and the indirect effect of X on Y through the
mediators. The specific indirect effect of X on Y through M1 is defined
by the product of the two paths linking X to Y through that mediator,
i.e., a1b1; similarly, the specific indirect effect of X on Y through M2
is defined by the product of the two paths linking X to Y through that
mediator, i.e., a2b2. The total indirect effects of X on Y is the sum of the
two specific indirect effects, i.e., a1b1 + a2b2; The total effect of X on Y is
thus the sum of the direct effect and all of the indirect effects: c = c′ +
a1b1 + a2b2; all analyses were adjusted for the following covariates:
age, sex, glucose metabolism status, smoking status, mean arterial
pressure, glycated hemoglobin (HbA1c), total-to-high-density lipoprotein
cholesterol ratio and triglycerides. HOMA-IR, insulin resistance derived
from the homeostasis model assessment.

Statistical analyses
All analyses were carried out with the use of the Statistical Package of
Social Sciences 15.0 for Windows (SPSS, Chicago, IL), and statistical
significance was set at P < 0.05.
Variables with a skewed distribution (i.e., triacylglycerol, insulin,
HOMA2-IR, CRP, IL-6, SAA and sCD25) were log10-transformed
prior to further analyses. ANOVA or χ2 tests were used, as appropriate,
1692

to compare subjects’ characteristics across tertiles of waist circumference. We computed a continuous “adaptive immune activation score”
by averaging the z-scores (i.e., (subject’s value−group’s mean)/group’s
s.d.) of neopterin and log10sCD25, and an “innate immune activation
score” by averaging the z-scores of log10CRP, log10IL-6, and log10SAA.
These scores enable a more robust characterization of the mechanisms represented and help overcome the problem of misclassification, the latter often leading to an underestimation of the strength of
the associations when each marker is analyzed separately.
Simple and multiple mediation analyses. When simple and/
or multiple mediation hypotheses are entertained, as in the present
study, the magnitude of the associations linking all the variables of
interest need to be established first (27). We have therefore used multiple linear regression analyses to ascertain: (i) the association between
waist circumference (X) and the adaptive immune activation score
(Y)—path c; (ii) the association between X and each of the mediators
(M(s)) proposed, i.e., innate immune activation score and IR—path(s)
a; and (iii) the association between the M(s) and Y, when controlling
for X and the other mediator in multiple mediation models—path(s)
b. Path c thus represents the total “effect” of X on Y, which can be
apportioned into the direct “effects” of X on Y (path c′) + the indirect
effect of X on Y through the M(s) (paths ab or c–c′)—Figure 1a,b,
for simple mediation and Figure 1a,c for multiple mediation models (28–30). All these analyses were performed with adjustments for
the following covariates: age, sex, glucose metabolism status, smoking
status and prior cardiovascular disease, and also for other risk factors,
i.e., HbA1c, mean arterial pressure, total-to-high-density lipoprotein
cholesterol ratio and triacylglycerol. Results hereby obtained were
reported as standardized regression coefficients (β) and respective
95% confidence intervals to enable comparison of the strength of the
associations investigated.
Traditionally, mediation is considered to be present when the
strength of the association between X and Y (path c) decreases by
a nontrivial amount after further adjustment for the M(s)—path c′;
the ratio of the indirect to the total “effects” (i.e., ab/c) is then often
interpreted as the proportion of the total effect that is mediated by the
mediator(s) (27,28). However, and according to recent recommendations regarding mediation data analyses procedures, this concept is
flawed in situations when c < ac (yielding proportion >1), c and ab
have different directions (yielding negative proportions), c = 0 (yielding a situation in which the proportion is undefined) or when c is
close to 0 (when any trivial mediation may seem massive) (28,31).
Instead, a better approach is to estimate the magnitude of the indirect “effect(s)” and the respective 95% confidence intervals, thereby
enabling the testing of whether such “effects” differ significantly from
0 (29). In addition, when multiple mediators are investigated, as in
the present case, contrasting the specific indirect “effects” attributable to one vs. the other mediator is of interest (30). Accordingly, we
computed bootstrapped (bias-corrected) confidence intervals (5,000
samples) for the size of the specific mediation “effects” using SPSS
macros provided by Preacher & Hayes (30). These analyses enabled
the appreciation of whether any of the proposed mediators exerts
a predominant role in the association investigated, thus contributing to a better understanding of the operative pathophysiological
mechanisms (28,30,31).
Results

Table 1 shows the general characteristics of the study population across tertiles of waist circumference. Subjects with
increasing levels of waist circumference were characterized by
a more adverse cardiovascular risk profile. Levels of markers
of adaptive and innate immune activation and their scores, as
well as HOMA2-IR, were also significantly increased across
tertiles of waist circumference.
VOLUME 19 NUMBER 8 | august 2011 | www.obesityjournal.org
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Table 1 Baseline characteristics of the study population according to tertiles of waist circumference
Tertiles of waist circumference
T1 (n = 163)
Sex, % men
Age, years

T2 (n = 154)

T3 (n = 160)

P for linear trend
<0.001

46.6

70.1

75.0

58.8 (7.4)

59.5 (7.1)

60.1 (6.3)

0.088

BMI, kg/m

25.0 (2.3)

28.0 (2.0)

32.3 (4.0)

<0.001

Waist circumference,a cm

87.4 (6.1)

98.4 (2.6)

111.8 (7.4)

<0.001

Systolic blood pressure, mm Hg

135.4 (19.4)

141.6 (19.1)

143.7 (16.5)

<0.001

Diastolic blood pressure, mm Hg

78.9 (8.6)

81.8 (9.3)

85.2 (8.3)

<0.001

Pulse pressure, mm Hg

56.5 (14.6)

59.8 (15.6)

58.5 (14.3)

0.225

Mean arterial pressure, mm Hg

97.7 (11.3)

101.7 (11.2)

104.7 (10.1)

<0.001

Antihypertensive treatment, %

30.7

28.6

48.8

<0.001
<0.001

2

Hypertension, %

44.2

66.2

73.8

Total cholesterol, mmol/l

5.19 (1.05)

5.30 (0.95)

5.11 (0.83)

LDL-cholesterol, mmol/l

3.23 (0.86)

3.43 (0.81)

3.21 (0.78)

0.870

HDL-cholesterol, mmol/l

1.33 (0.38)

1.18 (0.30)

1.07 (0.28)

<0.001

Total-to-HDL cholesterol ratio

4.15 (1.32)

4.81 (1.61)

5.08 (1.43)

<0.001

Triacylglycerol, mmol/l

1.0 (0.8–1.6)

Lipid-lowering medication, %

1.4 (1.0–1.9)

1.7 (1.3–2.2)

0.457

<0.001

17.2

13.6

20.6

0.416

Fasting plasma glucose, mmol/l

5. 61(1.02)

5.93 (1.14)

6.38 (1.52)

<0.001

Glycated hemoglobin, %

5.78 (0.62)

5.84 (0.61)

6.14 (0.89)

<0.001

Fasting plasma insulin, pmol/l
Insulin resistance (HOMA2-IR)

47 (38–57)
0.90 (0.72–1.09)

Glucose-lowering medication, %

59 (44–84)
1.14 (0.84–1.64)

83 (61–128)

<0.001

1.62 (1.20–2.48)

<0.001

6.1

10.4

15.6

0.006

64.4/21.5/14.1

57.8/20.8/21.4

41.3/25.0/33.8

<0.001

35.0/41.1/23.9

20.1/57.8/22.1

28.1/56.3/15.6

0.856

34.4

<0.001

Glucose metabolism status
NGM/IGM/DM2, %
Smoking status
Never/ex-/current smoker, %
Prior cardiovascular disease, %

17.2

27.3

C-reactive protein, mg/l

1.7 (1.0–3.8)

2.6 (1.5–4.3)

3.2 (1.9–5.7)

<0.001

Interleukin-6, pg/ml

1.1 (0.8–1.7)

1.3 (1.0–2.0)

1.8 (1.2–2.7)

<0.001

Serum amyloid A, µg/ml

6.4 (3.7–14.1)

8.0 (4.7–13.7)

8.0 (4.5–15.1)

0.099

Neopterin, nmol/l

5.88 (1.81)

6.24 (2.05)

6.56 (2.59)

0.005

Soluble CD25, μg/ml

2.33 (1.76–3.16)

2.64 (2.04–3.23)

2.61 (1.97–3.37)

0.021

Data are percentages, means (standard deviations) or median (inter-quartile ranges).
DM2, type 2 diabetes; HDL, high-density lipoprotein; HOMA2-IR, insulin resistance from the homeostasis model assessment; IGM, impaired glucose metabolism;
LDL, low-density lipoprotein; NGM, normal glucose metabolism; T1, lowest tertile; T2, middle tertile; T3, highest tertile.
a
Specific mean (s.d.) values in men were 89.4 (4.5), 98.4 (2.5), and 112.2 (7.7), and in women 85.6 (6.8), 98.5 (2.7), and 110.7 (6.3), for T1, T2, and T3, respectively.

Associations between waist circumference and markers
of adaptive and innate immune activation and IR

After adjustments for age, sex, glucose metabolism and smoking status, waist circumference was positively associated with
neopterin (β = 0.08 (95% confidence intervals: −0.01 to 0.18),
P = 0.090) and sCD25 (β = 0.16 (0.06 to 0.25), P = 0.002), as
well as the adaptive immune activation score (β = 0.12 (0.04 to
0.20), P = 0.002) (model 1) (Table 2). Further adjustments for
other risk factors did not materially affect these associations
(model 2). Waist circumference was also positively associated
with the innate immune activation score (β = 0.24 (0.17 to
obesity | VOLUME 19 NUMBER 8 | August 2011

0.31), P < 0.001) and each of its constituent markers (i.e., CRP,
IL-6, and SAA), as well as with HOMA2-IR (β = 0.55 (0.48
to 0.62), P < 0.001) (model 1). Again, further adjustments for
other risk factors did not change these associations appreciably
(β = 0.25 (0.18 to 0.32), and β = 0.49 (0.42 to 0.56), respectively,
both P < 0.001) (model 2).
Associations between (markers of) innate immune activation
and IR and (markers of) adaptive immune activation

The innate immune activation score (and each of its constituent markers) were positively and significantly associated with
1693
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Table 2 Associations of waist circumference with markers of adaptive and innate immune activation and with insulin resistance
Model 1

Model 2

β

95% CI

P value

β

95% CI

P value

Neopterin

0.08

−0.01; 0.18

0.090

0.09

−0.01; 0.19

0.084

Log10sCD25

0.16

0.06; 0.25

0.002

0.15

0.05; 0.25

0.004

Adaptive immune activation score

0.12

0.04; 0.20

0.002

0.12a

0.04; 0.20

0.004

Log10CRP

0.33

0.24; 0.42

<0.001

0.33

0.23; 0.42

<0.001

Log10IL-6

0.23

0.14; 0.32

<0.001

0.25

0.15; 0.35

<0.001

Log10SAA

0.16

0.07; 0.26

0.001

0.17

0.07; 0.27

0.001

Innate immune activation score

0.24

0.17; 0.31

<0.001

0.25b

0.18; 0.32

<0.001

0.55

0.48; 0.62

<0.001

0.49c

0.42; 0.56

<0.001

Dependent variables
Markers of adaptive immune activation

Markers of innate immune activation

Insulin resistance
Log10HOMA2-IR

Model 1, adjusted for age, sex, glucose metabolism, smoking status and prior cardiovascular disease. Model 2, model 1 + adjustments for mean arterial pressure, glycated hemoglobin (HbA1c), total-to-high-density lipoprotein cholesterol ratio and log10 triglycerides. The boldface values are used to construct Table 4.
β, standardized regression coefficient; indicates change in dependent variable (in s.d.) per s.d. increase in waist circumference; CI, confidence interval; CRP, C-reactive
protein; HOMA2-IR, insulin resistance derived from the homeostasis model assessment; IL-6, interleukin-6; SAA, serum amyloid A; sCD25, soluble CD25.
a
Path c. bPath a1. cPath a2 in multiple mediation analyses (see Figure 1).

neopterin, sCD25, and the adaptive immune activation score
(Table 3). These associations were independent of age, sex,
glucose metabolism, smoking status, prior cardiovascular disease (model 1), other risk factors (model 2), but also of waist
circumference (model 3) and HOMA2-IR (model 4a): β = 0.31
(0.21 to 0.40), P < 0.001, for the association between the innate
and the adaptive immune activation scores. After all adjustments (model 4b), HOMA2-IR was also positively and significantly associated with the adaptive immune activation score:
β = 0.11 (0.02 to 0.21), P = 0.021.
Mediating role of innate immune activation and/or IR
in the association between waist circumference
and adaptive immune activation

The strength of the association between waist circumference
and the adaptive immune activation score (β = 0.118 (0.038
to 0.197)) was attenuated and no longer significant when further adjusted for innate immune activation score (to β = 0.038
(−0.041 to 0.118), P = 0.346) or HOMA2-IR (to β = 0.048
(−0.044 to 0.141), P = 0.304), respectively (Table 4). The indirect associations of waist circumference on adaptive immune
activation score through the innate immune activation score
or through HOMA2-IR were both significant: β = 0.079
(0.050 to 0.117), P < 0.001 and β = 0.069 (0.021 to 0.128),
P = 0.011, respectively—simple mediation analyses. When
adjustments for both mediators were considered simultaneously, the association between waist circumference and the
adaptive immune activation score was completely abolished
to β = −0.013 (−0.104 to 0.077), P = 0.777, and thus the total
indirect associations through the mediators had a magnitude
of 0.131 (0.077 to 0.192), P < 0.001. Analyses performed in
order to tease apart the specific relative contribution of the
immune activation score and of HOMA2-IR as mediators
of this association showed that these had a magnitude of
1694

β = 0.076 (0.048 to 0.115), P < 0.001 and β = 0.054 (0.006 to
0.111), P = 0.041, or 58% vs. 42%, respectively, which were not
statistically different from each other, however (β = −0.022
(−0.087 to 0.043), P = 0.508).
Additional analyses

We also conducted analyses with BMI, instead of waist circumference, as main determinant of adaptive immune activation. All associations, including the mediation role of innate
immune activation and HOMA2-IR, were very similar to
those reported herein (data not shown). low-density lipoprotein–lowering drugs including statins have been demonstrated
to exert immunosuppressive activities (reviewed in ref. 32).
However, none of the associations described herein changed
materially after further adjustments for the use of lipid-lowering medication (data not shown). Replacing mean arterial
pressure by systolic blood pressure or hypertension as a covariate in our models also did not change any of the estimates
reported (data not shown).
Discussion

The main findings of the present study are threefold. First,
waist circumference, a marker of abdominal fat mass, is associated not only with higher systemic levels of markers of innate
immune activation and IR but also with higher levels of markers of adaptive immune activation. Second, the association
between abdominal fat and adaptive immune activation is
completely explained, i.e., mediated, by abdominal fat–related
elevations in innate immune activation and IR. Finally, each
of these mediators represents independent pathways of similar importance linking abdominal fat to adaptive immune
activation.
Using a flow-cytometric approach, adaptive immune activation has recently been demonstrated in morbidly obese study
VOLUME 19 NUMBER 8 | august 2011 | www.obesityjournal.org
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Table 3 Associations of markers of innate immune activation and insulin resistance with markers of adaptive immune
activation
Neopterin
Independent variables

Model

β

1

0.16

2
3

Adaptive immune
activation score

Log10sCD25
P value

β

95% CI

P value

β

95% CI

P value

0.07; 0.25

0.001

0.24

0.15; 0.33

<0.001

0.20

0.13; 0.27

<0.001

0.16

0.07; 0.25

0.001

0.21

0.12; 0.30

<0.001

0.19

0.11; 0.26

<0.001

0.15

0.05; 0.25

0.003

0.19

0.09; 0.28

<0.001

0.17

0.09; 0.24

<0.001

4a

0.14

0.04; 0.24

0.004

0.18

0.08; 0.27

<0.001

0.16

0.09; 0.24

<0.001

1

0.31

0.22; 0.40

<0.001

0.28

0.18; 0.37

<0.001

0.29

0.22; 0.36

<0.001

2

0.31

0.22; 0.40

<0.001

0.25

0.16; 0.34

<0.001

0.28

0.21; 0.35

<0.001

95% CI

Markers of innate immune activation
Log10CRP

Log10IL-6

Log10SAA

Innate immune activation score

3

0.31

0.22; 0.40

<0.001

0.23

0.14; 0.33

<0.001

0.27

0.20; 0.34

<0.001

4a

0.30

0.21; 0.40

<0.001

0.23

0.13; 0.32

<0.001

0.26

0.19; 0.34

<0.001

1

0.15

0.06; 0.24

0.001

0.11

0.02; 0.20

0.021

0.13

0.06; 0.20

0.001

2

0.15

0.06; 0.24

0.001

0.11

0.02; 0.20

0.018

0.13

0.06; 0.21

<0.001

3

0.14

0.05; 0.24

0.002

0.09

0.00; 0.19

0.049

0.12

0.05; 0.19

0.002

4a

0.14

0.05; 0.23

0.004

0.08

−0.01; 0.17

0.088

0.11

0.04; 0.18

0.004

1

0.34

0.23; 0.46

<0.001

0.35

0.23; 0.47

<0.001

0.35

0.26; 0.44

<0.001

2

0.35

0.23; 0.46

<0.001

0.32

0.20; 0.44

<0.001

0.33

0.24; 0.42

<0.001

3

0.35

0.22; 0.47

<0.001

0.29

0.17; 0.42

<0.001

0.32a

0.22; 0.41

<0.001

4a

0.34

0.22; 0.46

<0.001

0.28

0.16; 0.40

<0.001

0.31

0.21; 0.40

<0.001

1

0.12

0.02; 0.21

0.021

0.22

0.13; 0.32

<0.001

0.17

0.09; 0.25

<0.001

2

0.12

0.02; 0.23

0.022

0.21

0.11; 0.32

<0.001

0.17

0.08; 0.25

<0.001

3

0.10

−0.02; 0.23

0.102

0.18

0.06; 0.30

0.004

0.14b

0.04; 0.24

0.004

4b

0.07

−0.05; 0.19

0.257

0.15

0.03; 0.27

0.013

0.11

0.02; 0.21

0.021

c

Insulin resistance
Log10HOMA2-IR

d

Model 1, adjusted for age, sex, glucose metabolism, smoking status and prior cardiovascular disease. Model 2, model 1 + adjustments for mean arterial pressure,
glycated hemoglobin (HbA1c), total-to-high-density lipoprotein cholesterol ratio and log10 triglycerides; Model 3, model 2 + adjustment for waist circumference; Model 4a,
model 3 + adjustment for log10HOMA2-IR; Model 4b, model 3 + adjustment for innate immune activation score. The boldface values are used to construct Table 4.
β, standardized regression coefficient; indicates change in dependent variable (in s.d.) per s.d. increase in independent variable; CI, confidence interval; CRP, C-reactive
protein; HOMA2-IR, insulin resistance derived from the homeostasis model assessment; IL-6, interleukin-6; SAA, serum amyloid A.
a
Path b1 and bpath b2 in simple mediation analyses (see Figure 1); cPath b1 and dpath b2 in multiple mediation analyses (see Figure 1).

subjects (33). Positive associations between measures of (central) obesity and neopterin have previously been shown in a
large cohort of apparently healthy individuals (34) and two
small studies on healthy and obese individuals (35,36). We
have now confirmed but also extended those findings to yet
another marker of adaptive immune activation—sCD25—in a
relatively large cohort of individuals at increased risk of type 2
diabetes and cardiovascular disease. In addition, this is the first
study that has investigated not only the association between
abdominal fat and markers of adaptive immune activation,
but also potential underlying mechanisms explaining any such
associations.
Recent papers suggest that T lymphocytes are critically
involved in the regulation of adipose tissue inflammation.
Nishimura and colleagues showed that adipose tissue CD8+
T cells have an essential role in macrophage recruitment (12).
CD4+ effector cells can generally be divided into proinflammatory cells (T helper (Th)1, Th17), and anti-inflammatory cells
and regulatory sublineages (Th2, Tregs). In adipose tissue in
obesity | VOLUME 19 NUMBER 8 | August 2011

lean mice, Th2 and Treg cells predominate and these cells seem
to be critically involved in the regulation of body weight, adipose tissue inflammation and IR (13,14). In both human and
mice, there is a shift in adipose tissue T-cell populations so that
CD8+ and Th1 T cells dominate (13). Th1-derived interferon-γ
is classically known to activate macrophages. This process may
augment proinflammatory cytokine (like IL-1β, tumor necrosis factor-α, and IL-6) production in the adipose tissue and
these molecules may then be released into the systemic circulation. Indeed, the present study confirms that serum levels of
tumor necrosis factor-α, IL-6, and acute phase reactants such
as CRP and SAA are higher in individuals with greater levels
of (central) obesity (15).
The involvement of innate and adaptive immune components in the inflammatory process at the local level (i.e., in
adipose tissue) may differ from that at the systemic circulation level. In adipose tissue, adaptive immune cells (T cells)
appear to initiate and regulate innate immune cells and hereby
IR, whereas in the systemic circulation the adaptive immune
1695
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Table 4 Association between waist circumference and adaptive immune activation score, and the total and specific mediation
role of innate immune activation and insulin resistance herein
Simple mediation analyses
By innate immune
activation score

Multiple mediation analyses
By innate immune
activation and
log10HOMA2-IR

β

95% CI

P value

β

95% CI

P value

Specific
mediation
(%)a

0.118

0.038; 0.197

0.004

0.118

0.038;
0.197

0.004

—

<0.001

—

—

—

0.248

0.175;
0.321

<0.001

—

—

—

0.490

0.416; 0.564

<0.001

0.490

0.416;
0.564

<0.001

—

0.319

0.224;
0.414

<0.001

—

—

—

0.307

0.212;
0.402

<0.001

—

—

—

—

0.141

0.044; 0.238

0.005

0.111

0.017;
0.204

0.021

—

0.038

−0.041;
0.118

0.346

0.048

−0.044; 0.141

0.304

−0.013

−0.104;
0.077

0.777

—

Total indirect association through
mediator(s) (c–c′)

0.079

0.050;
0.117

<0.001

0.069

0.021; 0.128

0.011

0.131

0.077;
0.192

<0.001

—

Specific indirect association
through innate immune
activation score (a1b1)

—

—

—

—

—

—

0.076

0.048;
0.115

<0.001

58%

Specific indirect association
through log10HOMA2-IR (a2b2)

—

—

—

—

—

—

0.054

0.006;
0.111

0.041

42%

—

—

—

—

—

−0.022

−0.087;
0.043

0.508

—

β

95% CI

P value

Waist → adaptive immune
activation score

0.118

0.038;
0.197

0.004

a1

Waist → innate immune
activation score

0.248

0.175;
0.321

a2

Waist → log10HOMA2-IR

—

b1

Innate immune activation
score → adaptive immune
activation score

b2

Log10HOMA2-IR →
adaptive immune
activation score

c′

Waist → adaptive immune
activation score
(– mediator(s), i.e., c–ab)′

Path

Description

c

By log10HOMA2-IR

Mediation analyses

Comparison of specific indirect
associations through innate
immune activation score vs.
log10HOMA2-IR

All associations are adjusted for the following covariates: age, sex, glucose metabolism, smoking status, prior cardiovascular disease (CVD), mean arterial pressure,
glycated hemoglobin (HbA1c), total-to-high-density lipoprotein cholesterol ratio and log10 triglycerides.
β, are standardized regression coefficients; CI, confidence interval; HOMA2-IR, insulin resistance derived from the homeostasis model assessment.
a
Calculated as proportion of the total indirect effects attributed to the specific mediators: i.e., 0.076/0.131 × 100 for innate immune activation and 0.054/0.131 × 100
for log10HOMA2-IR.

system may get involved as a result of adipose-related increases
in innate immune activation and/or IR. Our data are consistent with this hypothesis which can find some support from the
following observations. Proinflammatory cytokines, derived
from innate immune cells, may lower the threshold for peripheral T-cell activation (37). In addition, maturation, and consequently the ability of antigen-presenting cells to elicit a T-cell
response, may be enhanced in an inflammatory microenvironment (38). Nevertheless, T-cell activation is critically dependent on specific triggering of the T-cell receptor. The triggers
for the observed obesity-associated systemic T-cell activation
remain speculative although there is abundant expression of
candidate T-cell–triggering antigens in obese subjects.
IR was the other important mediator in the observed association between abdominal fat and adaptive immune activation. Besides the regulation of glucose and lipid metabolism,
a number of other biological functions have been assigned to
insulin, including an anti-inflammatory function. The effects
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of insulin on T-cell function have not yet been unraveled,
although Viardot et al. demonstrated that insulin can direct
polarization of effector T cells toward a Th2 phenotype (39).
The inability of T cells to respond to insulin, e.g., T-cell IR,
might result in a more Th1-polarized T-cell compartment.
Since neopterin is a product of interferon-γ–activated macrophages, the higher neopterin levels in subjects in the highest
tertile of waist circumference suggest that the Th1 T-cell compartment in these subjects is in a more activated state. The low
level of insulin sensitivity in this group of subjects might have
contributed to this.
The role of the adaptive immune system in the pathogenesis of obesity-related vascular complications remains speculative. Guzik et al. showed that T cells and T-cell–derived
tumor necrosis factor-α and IL-17 are involved in the pathogenesis of hypertension (40,41). In addition, subsets of T cells
have been demonstrated to play critical roles in atherogenesis (reviewed in ref. 42). The presence of activated T cells in
VOLUME 19 NUMBER 8 | august 2011 | www.obesityjournal.org
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atheromatous lesions implies that these cells are involved in
a specific immune reaction, probably directed against locally
expressed or formed (auto)antigens, e.g., oxidized low-density
lipoprotein (43). T lymphocytes can influence atherogenesis
progression by regulating the magnitude of the inflammatory
response within the plaque, as well as plaque stability and the
propensity for thrombus formation. Further research in this
area is nevertheless needed.
Limitations of the present study have to be taken into
account. First, the separation of markers into markers of innate
or adaptive immune activation is not absolute. IL-6 can also be
made by T cells, but macrophages and adipocytes are primary
sources. In addition, sCD25 is predominantly released from
activated T cells, although it may also be released from activated B cells and natural killer cells. Upon activation, Th1 cells
secrete large amounts of interferon-γ, which will subsequently
trigger neopterin release from monocytes (44). Although
monocytes belong to the innate immune system, neopterin is
not released in the absence of T-cell activation. Consequently,
neopterin is considered to be a marker of adaptive immune
cell activation. Second, our research questions were addressed
within the context of a cross-sectional study design, which
hinders definite conclusion in terms of causality. Indeed,
although we hypothesized and tested “causal models” linking abdominal fat to (markers of) adaptive immune activation
through abdominal fat–related increases in innate immune
activation and/or IR pathways, we cannot discard the possibility of reverse causation. In other words, associations between
abdominal fat and innate inflammation and/or IR could (also)
be explained, i.e., mediated, by abdominal fat–related increases
in adaptive immune activation. Indeed, additional analyses
testing these reverse causation models also showed that these
pathways could be operative, but with much smaller mediating
magnitudes (13 and 3%, respectively) than the ones reported
under our primary hypothesis (data not shown). Longitudinal
and time-lagged data are thus needed to further investigate the
directions of the associations tested. Finally, our study population consisted of middle-aged and older white individuals
at high risk for type 2 diabetes and cardiovascular disease.
Caution is thus needed in the extrapolation of our findings to
other populations (i.e., younger and/or healthier and of other
ethnicities).
In conclusion, on the basis of multiple mediation analyses, our data suggest that the associations between abdominal obesity and adaptive immune activation could be due to
obesity-related innate immune activation and IR. Further
research is needed to gain more insight into the triggers of the
observed abdominal fat–related T-cell activation and to elucidate the role of the adaptive immune system, and more specifically of T cells, in the pathogenesis of obesity-related vascular
complications.
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